Literature DB >> 26796800

[Inhibitory effect of a Chinese medicine Xiaoaiping combined with cisplatin on the proliferation, invasion and apoptosis in ovarian cancer HO-8910 PM cells in vitro and in vivo].

Aiwen Zheng1, Tao Li2, Yaqing Chen1, Jing Fang3, Yingli Zhang1, Jianguo Feng3.   

Abstract

OBJECTIVE: To explore the effect of a Chinese medicine, Xiaoaiping, in combination with cisplatin on the proliferation, invasion and apoptosis in human ovarian cancer HO-8910PM cells in vitro and vivo.
METHODS: CCK-8 assay was used to detect the inhibitoty effect of Xiaoaiping alone or in combination with cisplatin on the proliferation of human ovarian cancer HO-8910PM cells. Flow cytometry was used to detect the apoptosis and cell cycle distribution. Transwell migration test was used to assay the effect of drugs on the cell invasive capability. Changes of the tumor volume in nude mice were observed to evaluate the antitumor effects in vivo.
RESULTS: CCK-8 assay Xiaoaiping alone or combined with cisplatin could inhibit the proliferation of HO-8910PM cells with a dose-dependent manner. The inhibition rates of Xiaoaiping combined with cisplatin were (53.4±3.0)%, significantly increased than those with single drug (P<0.05). Flow cytometry showed that G0/G1 fraction was increased respectively from (64.2±1.6)% to (74.1±1.6)% and (68.6±1.6)%. The percentages of apoptotic cells were increased from (2.2±1.6)% to (16.1±1.6)%, (35.6±1.6)% after treated with Xiaoaiping, Cisplatin and combination drugs (P<0.05 for all). Transwell chamber with matrigel assay showed that number of cells penetrating through membrane in HO-8910PM cells was (89.2±20.7)/HPF in the drug combination group, significantly less than that in the control group(187.2±24.6)/HPF, Xiaoaiping(141.8±13.7 )/HPF or cisplatin group (155.8±19.4)/HPF (P<0.01 for all). The inhibition rate of drug combination group in the nude mouse transplanted tumors, compared with that of single Xiaoaiping and cisplatin group, was increased significantly (59.0% vs. 23.4% and 34.2%), (P<0.01 for both).
CONCLUSION: The results of our in vitro and vivo experiments indicate that Xiaoaiping can inhibit cell proliferation, increase G0/G1 arrest, promote apoptosis, inhibit cell migration of human ovarian cancer HO-8910 PM cells, and can synergistically enhance the antitumor activity of cisplatine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26796800     DOI: 10.3760/cma.j.issn.0253-3766.2016.01.003

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  5 in total

1.  Extract of Marsdenia tenacissima (Roxb.) Moon [Apocynaceae] Suppresses Hepatocellular Carcinoma by Inhibiting Angiogenesis.

Authors:  Yating Pan; Xinyi Liao; Lili Yang; Chunlei Zhang; Jue Wang; Peiyong Zheng; Guanzhen Yu; Haiyan Song
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

2.  Effect of traditional Chinese medicine (TCM) on survival, quality of life, and immune function in patients with ovarian carcinoma: A protocol for systematic review and meta analysis.

Authors:  Shuxia Ge; Qianqian Xing; Anqi Zhang; Yucui Wang
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

3.  Xiaoaiping injection combined with chemotherapy for advanced gastric cancer: An updated systematic review and meta-analysis.

Authors:  Xing Qin Zhou; Ya Zhou Chang; Chao Yan Shen; Jie Han; Ren An Chang
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

4.  Xiaoaiping injection as adjunct therapy for patients with advanced esophageal carcinoma: A protocol for a systematic review and meta-analysis.

Authors:  Zhen Liu; Yanling Dong; Meili Zhu; Ying Mu; Lemei Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

Review 5.  Comparative Efficacy of Chinese Herbal Injections Combined with Paclitaxel Plus Cisplatin for Non-Small-Cell Lung Cancer: A Multidimensional Bayesian Network Meta-Analysis.

Authors:  Mengwei Ni; Haojia Wang; Miaomiao Wang; Wei Zhou; Jiarui Wu; Bin Sun; Qianqian Zhang; Xiaotian Fan; Dan Zhang; Zhiwei Jing; Jingyuan Zhang; Xinkui Liu; Shuyu Liu; Ziqi Meng; Siyu Guo; Shanshan Jia; Xiaomeng Zhang; Xiaoguang Sheng
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-28       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.